GeneQuantum Healthcare (Suzhou) Co., Ltd.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
See more in Biomedtracker

Latest on GeneQuantum Healthcare (Suzhou) Co., Ltd.

Scrip

Chinese ADC Developers Forge Domestic Alliances To Push R&D

 
• By Dexter Jie Yan

Since the beginning of 2023, it seems that Chinese-originated antibody-drug conjugates (ADCs) have suddenly sprinted from stealth mode into the spotlight on the global biopharma collaboration stage. A

Scrip

Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas To Select Up To Five Targ

Scrip

Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S

Scrip

Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy

 
• By Joseph Haas, Ian Haydock, Dexter Jie Yan, Jung Won Shin, and Anju Ghangurde

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Bangladesh Acquisition Adds To B